Denali Therapeutics Inc
(NAS:DNLI)
$
27.96
0.88 (3.25%)
Market Cap: 4.00 Bil
Enterprise Value: 3.03 Bil
PE Ratio: 0
PB Ratio: 2.79
GF Score: 57/100 Denali Therapeutics Inc to Present Phase 1/2 Study of DNL310 Presentation Transcript
Jul 25, 2021 / 03:30PM GMT
Laura Hansen
Denali Therapeutics Inc. - VP of IR
Presentation
Jul 25, 2021 / 03:30PM GMT
=====================
Corporate Participants
=====================
* Carole Ho
Denali Therapeutics Inc. - Chief Medical Officer & Head of Development
* Laura Hansen
Denali Therapeutics Inc. - VP of IR
* Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
=====================
-
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot